Safi, Seyer and Yamauchi, Yoshikane and Rathinasamy, Anchana and Stamova, Slava and Eichhorn, Martin and Warth, Arne and Rauch, Geraldine and Dienemann, Hendrik and Hoffmann, Hans and Beckhove, Philipp (2017) Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer. ONCOIMMUNOLOGY, 6 (11): e1360458. ISSN 2162-402X,
Full text not available from this repository. (Request a copy)Abstract
In this prospective study, we examined postoperative follow-up and preoperative IFN-gamma T cell responses against 14 non-small cell lung cancer (NSCLC)-associated antigens in the blood of 51 patients with NSCLC, 7 patients with benign pulmonary tumors, and 10 tumor-free patients by enzyme-linked immunospot assay. The phenotype and function of T cells specific for tumor-associated antigens (TAAs) in the blood or tumor tissue of 9 NSCLC patients were characterized in detail using TNF-alpha, IL-2, and IFN-gamma cytokine capture assays. We found that circulating TAA-specific T cells were significantly enriched in NSCLC compared with tumor-free patients. The most frequently recognized TAAs were Aurora kinase A, HER2/neu, NY-ESO-1, and p53. TNF-alpha was the most abundant cytokine secreted by TAA-specific T cells in the blood as well as by in situ-activated tumor-infiltrating lymphocytes, most of which were effector memory cells. The absence of TAA-reactive T cells identified patients at higher risk of tumor recurrence, irrespective of tumor stage (OR = 8.76, 95% CI: 1.57-34.79, p = 0.008). We conclude that pre-existing TAA-reactive circulating T cells are a strong independent prognostic factor for recurrence-free survival. These data may help discriminating high-risk from lowrisk patients, improving prognostication, and redirecting adjuvant therapy. Our findings suggest the therapeutic relevance of Aurora kinase A, HER2/neu, NY-ESO-1, and p53 as targets for immunotherapy.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | METASTASIZED BREAST-CANCER; BONE-MARROW; IMMUNE-RESPONSE; FOLLOW-UP; VACCINE; IMMUNOTHERAPY; GUIDELINES; PROGNOSIS; THERAPY; SUBSETS; Immunotherapy; non-small cell lung cancer; survival; memory T cells; tumor-associated antigens |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Regensburger Centrum für Interventionelle Immunologie (RCI) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Dec 2018 13:01 |
| Last Modified: | 20 Feb 2019 14:49 |
| URI: | https://pred.uni-regensburg.de/id/eprint/634 |
Actions (login required)
 |
View Item |
